Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06375811 · ClinicalTrials.gov registry record · Phase 3
Pre-IVF Treatment With a GnRH Antagonist in Women With endometriosis_temp
A Phase 3 study of Infertility and Endometriosis, sponsored by Yale University.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 297
- Enrollment target
- 5
- Study locations
NCT06375811: Recruiting Phase 3 study of Infertility and Endometriosis, sponsored by Yale University.
NCT06375811 is a Phase 3 study of Infertility and Endometriosis that is actively recruiting participants, run by Yale University. The registered enrollment target is 297 participants, below the 7,585-participant average among 74 other Infertility trials with a reported enrollment target (96% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06375811, a Phase 3 study of Infertility and Endometriosis, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 297 participants
- Enrollment target
- 5
- Study locations
Study Summary
A Phase 3 clinical trial of oral GnRH antagonist pre-treatment for women with endometriosis who are undergoing IVF, with a primary outcome of live birth rate. The investigators' central hypothesis is that in infertile woman with endometriosis undergoing in vitro fertilization-embryo transfer (IVF-ET), live birth rates will improve in those pretreated with GnRH antagonist compared to those not pretreated with GnRH antagonist.
Primary Outcome
Live birth rate per participant is defined as live birth at ≥24 weeks of gestation.
Conditions Studied
Interventions
- DRUG Elagolix 200 MG
- OTHER Placebo or SOC IVF
Study Locations (5)
Colorado
- University of Colorado Department of Obstetrics & Gynecology - Aurora
Connecticut
- Yale School of Medicine Dept.of Ob/Gyn & Reproductive Sciences - New Haven
Illinois
- Northwestern University Department of Obstetrics and Gynecology - Chicago
Maryland
- Johns Hopkins, Division of Reproductive Science and Women's Health Research - Baltimore
North Carolina
- Duke Fertility - Morrisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 297 participants |
| Start Date | 2024-03-16 |
| Est. Completion | 2026-09-30 |
| Phase | Phase 3 |
What NCT06375811 shows while recruiting
NCT06375811 is an interventional study that assigns participants to a tested intervention. The registered 297 participants enrollment target is mid-sized for trials with a published cap, below the 7,585-participant average among 74 other Infertility trials with a reported enrollment target (96% lower).
The record links to 2 conditions, with Infertility appearing as the primary indexed condition, and to 2 interventions - of which Elagolix 200 MG is the first listed.
NCT06375811 lists 5 locations in 5 states (Colorado, Connecticut, Illinois).
Frequently Asked Questions
What is clinical trial NCT06375811 about?
NCT06375811 is a clinical study titled "Pre-IVF Treatment With a GnRH Antagonist in Women With endometriosis_temp". A Phase 3 clinical trial of oral GnRH antagonist pre-treatment for women with endometriosis who are undergoing IVF, with a primary outcome of live birth rate. The investigators' central hypothesis is that in infertile woman with endometriosis undergoing in vitro fertilization-embryo transfer (IVF-ET...
What is the current status of trial NCT06375811?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 297 participants. The study started on 2024-03-16. Estimated completion is 2026-09-30.
What conditions does trial NCT06375811 study?
This clinical trial studies the following conditions: Infertility, Endometriosis.
What interventions are being tested in trial NCT06375811?
The interventions under investigation include: Elagolix 200 MG (DRUG), Placebo or SOC IVF (OTHER).
Who is sponsoring clinical trial NCT06375811?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06375811 being conducted?
This trial has 5 study locations across Colorado, Connecticut, Illinois, Maryland, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Infertility
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06375811's enrollment target sits among peer trials
297 34th of 74 higher than 41 of 74 other Infertility trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Infertility trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial
RECRUITING · Phase 3
-
Subcutaneous Progesterone in Frozen- Thawed Single Euploid Blastocyst Transfer.
ACTIVE NOT RECRUITING · Phase 3
-
Vaginal Culture Using INVOcell Compared to Traditional IVF Incubation
COMPLETED · Phase 3
-
Comparison of MENOPUR Liquid and Powder in Women Undergoing Assisted Reproductive Technology (ART)
COMPLETED · Phase 3
-
A Clinical Trial to Evaluate the Efficacy and Safety of DR-2011 for In Vitro Fertilization
COMPLETED · Phase 3
-
Gamete Treatment to Correct Fertilization Failure
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06309160 · 297 participants · NA
COMPASS Across Settings (CAST) for Improving Transition Outcomes for Students With ASD
- NCT07222215 · 297 participants · Phase 2
PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
- NCT06305624 · 298 participants · NA
Implementation of Mobile-based Programs for Alcohol Cessation in Treatment of Alcohol-associated Liver Disease
- NCT06754215 · 298 participants · NA
Smoking Cessation Intervention Development for Homeless Youth
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI